<DOC>
	<DOCNO>NCT01597531</DOCNO>
	<brief_summary>The purpose study determine whether addition 1 2 medicine gastric band improve remission type 2 diabetes .</brief_summary>
	<brief_title>Combinatorial Therapy Peristent Type 2 Diabetes After Gastric Banding</brief_title>
	<detailed_description>Liraglutide Orlistat improve glycemic control increase glucagon-like-peptide-1 ( GLP-1 ) response fat malabsorption , respectively reverse type 2 diabetes . Roux-en-y gastric bypass ( RYGB ) surgery reverse type 2 diabetes 84 % time less invasive , reversible laparoscopic adjustable gastric banding ( LAGB ) procedure reverse type 2 diabetes 48 % time . Decreased caloric intake occur RYGB LAGB increase post-prandial GLP-1 response fat malabsorption occur RYGB . Since FDA-approved agent Liraglutide Orlistat increase GLP-1 response fat malabsorption , respectively , significant clinical interest determine addition Liraglutide and/or Orlistat improve type 2 diabetes remission rate 52 % patient achieve diabetes reversal gastric banding .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects eligible meet follow criterion : male female , age 2570 year , BMI 2665 , type 2 diabetic , weight stable 3 month , status post laparoscopic adjustable gastric banding ( LAGB ) least 1 year , hemoglobin a1c 710 % ; diabetic regimen include insulin except thiazolidinedione use past 6 month . Subjects exclude meet follow criterion : prior history pancreatitis , prior history gastroparesis , glomerular filtration rate ( GFR ) &lt; 50 , history thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer , history cholelithiasis , history hyperoxaluria calcium oxalate nephrolithiasis , abnormal AST , ALT elevation , current past history liver disease , history Rouxeny gastric bypass gastric sleeve bariatric procedure LAGB , type 1 diabetes , gastrointestinal disease cause malabsorption ( include limit inflammatory bowel disease , celiac sprue ) , prior history Orlistat incretin therapy use past 3 month , unwilling unable complete schedule testing , thiazolidinedione use within past 6 month , serious and/or unstable medical , psychiatric , condition ( ) prevent patient provide informed consent comply study . Patients organ transplantation chronic anticoagulation , pregnant A1C value &gt; 10 % also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Liraglutide</keyword>
	<keyword>Orlistat</keyword>
</DOC>